Get started

Pharmaceuticals

Pharmamar PHMGood morning, today I present the analysis of PHM, a Spanish company pharmamar in the race for the vaccine against Covid19. It is being a great trading year for this company. The bullish structure marked by the yellow arrow has been broken, but the new structure, the bearish one, has not yet consolidated. You have marked supports and resistances to see possible changes in trend ... We mark some of them, the purple and blue arrows. Sincerely L.E.D Be Safe!! In Spain on 10/20/2020
BME:PHMLong
by wallstreetstocks
BioNTech Stock Will Soar With Its First-Mover Vaccine AdvantageNASDAQ:BNTX a German company and its american partner NYSE:PFE will likely have a first-mover advantage in the coronavirus vaccine race in the U.S. This will affect both stocks, once the final vaccine results are in. Assuming the bottom is in and we are about to continue the Trend as previously, im expecting a big move after the approval, so dont forget to take risk of the table! The reason for this is that the two companies are expecting to be the first to produce large-scale results from their Phase 2/3 clinical trials in October, according to Barron’s. Depending on how effective their vaccine is, the U.S. Food and Drug Administration may even grant it emergency-use authorization The advantage of their trial is that it is large, involving more than 30,000 participants. The FDA wants to see at least 50% efficacy in trials before granting any Covid-19 authorization. Why BioNTechs Vaccine Looks Like a Winner With Pfizer in the back FDA and President Donald Trump are likely to move quickly. According to them even the first small study with 24 Persons that took their messenger RNA vaccine produced antibodies. With a lower doses usage of the vaccine and developed antibodies after 28 days — at levels about two times higher than in normal, recovering Covid-19 patients. BioNTech and Fosun Pharma to Potentially Supply 10 Million Doses of BioNTech’s BNT162 to Hong Kong SAR and Macao SAR Also a Deal to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidat This combined with the huge buying volume and market shifts will grant momentum for bigger goals. Just think about what ccould happen when they get kinda a monopol situation going for them. Thank you for take the time and reading this and as always stay storng in those shaky times! Sebastian
NASDAQ:BNTXLong
by Sebastian-TradingExpertsEU
4
Merck a strong value with strong technicals and upcoming newsI've been holding Merck since its big dip to $76 back in June. At the time I set a price target of $82: However, I didn't sell at $82 and have continued to hold the stock due to strong fundamentals, technicals, news, and sentiment. Merck has positive earnings and sales growth, with PEG ratio of 1.7 and PSG ratio of 2.3. It has a nice dividend yield at 2.9%, a rarity for a stock with such strong growth. Analysts rate it highly, with an average score of 80.25/100 from S&P Global and an Equity Starmine Summary Score of 8.5/10. With a put/call ratio of 0.41, sentiment on Merck is stronger than on most of the other stocks I watch. It's got a good ESG score and a long history of beating analyst estimates. Plus it's poised to benefit from some hype around its antiviral drug intended to fight Covid-19 that starts clinical trials in September. In technical terms, Merck recently broke out of a triangle, got a couple bullish moving average crosses, and today broke out above its recent trading range. If Merck oscillates down to its moving averages, I may use that as an opportunity to add to my position. I think the stock still has plenty of upside, especially when the clinical trial headlines start to hit.
NYSE:MRKLong
by ChristopherCarrollSmith
BIOSEARCH: Potential H&S despite good fundamentalsOn July 10, after issuing a warning that the firm would expect higher than usual profits, BIOS jumped >20% that friday. Then, once its quarterly earnings were released, it was clear the company had not tricked us: + 25.8% REVENUES OF 14.3 MILLION IN THE FIRST SEMESTER, +44.2% to 5.5 million euros in Plant extracts business line, probiotics business registered a growth of 47.4%, standing at 3.2 million euros, driven mainly by the Women’s Health segment. Net profit was up +501,7% in the first semester of 2020. EBITDA of €1,96 million (+92,8% Semester over Semester). However, technical analysis suggests to short the company until 1.04 or even 0.95 level (and some other analysts from FX Street say 0.87). As it is usual in summer, the company is experiencing low volume levels so if volume starts increasing, BIOS' share price may go up easily as Reig Jofre or ROVI did. So, long-term trend is bullish up until 2018 maximums of 1.95-2€. August is bearish. relatively high PER: (57*1.13)/1.04 = 62 Not higher than RJFE's PER = 77 ROVI's PER = 95 And lower than: FAES FARMA PER = 21.53 (very undervalued in my opinion) PHARMA MAR PER = 14 (unstable company, needs more history to determine its viability. it could certainly be a good investment due to its low PER, but remember first semester 2019 it experienced losses instead of profits) These PERs here were calculated based on net profit from first semester 2020 only.
BShort
by alexinve